Axsome Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Axsome Therapeutics has a total shareholder equity of $102.9M and total debt of $179.3M, which brings its debt-to-equity ratio to 174.4%. Its total assets and total liabilities are $548.2M and $445.4M respectively.
Key information
174.4%
Debt to equity ratio
US$179.33m
Debt
| Interest coverage ratio | n/a |
| Cash | US$315.66m |
| Equity | US$102.85m |
| Total liabilities | US$445.37m |
| Total assets | US$548.23m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AXSM *'s short term assets ($463.0M) exceed its short term liabilities ($186.6M).
Long Term Liabilities: AXSM *'s short term assets ($463.0M) exceed its long term liabilities ($258.8M).
Debt to Equity History and Analysis
Debt Level: AXSM * has more cash than its total debt.
Reducing Debt: AXSM *'s debt to equity ratio has increased from 80.6% to 174.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXSM * has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AXSM * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.